Lil­ly en­lists a long-in­cu­bat­ing RNA up­start in new $1.25B part­ner­ship

For near­ly a decade af­ter Im­pe­r­i­al Col­lege Lon­don pro­fes­sor Nagy Habib launched Mi­NA Ther­a­peu­tics around a new kind of RNA in 2008, the com­pa­ny made vir­tu­al­ly no an­nounce­ment: no ven­ture cap­i­tal raised, no col­lab­o­ra­tions signed. Now, it’s like a fire hose.

On Tues­day, Mi­NA an­nounced a re­search col­lab­o­ra­tion with Eli Lil­ly worth up to $1.25 bil­lion: $25 mil­lion up­front and $245 mil­lion in mile­stones for each of five po­ten­tial tar­gets. The col­lab­o­ra­tors didn’t di­vulge what those tar­gets would be, but said they would come in Lil­ly’s “key ther­a­peu­tic ar­eas,” such as meta­bol­ic dis­eases and dis­eases of the cen­tral ner­vous sys­tem.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.